ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Proteases >Cysteine ??Protease Inhibitors >MK-0822

MK-0822

CAS No.: 603139-19-1

Chemical Name:: MK-0822

Synonyms: CS-700;MK-0822;ODANACATIB;MK-0822;MK0822;Unii-N673F6W2vh;Odanacatib, >=98%;Odanacatib(Mk0822);(MK0822,Odanacatib);Odanacatib,MK-0822,MK0822;Pentanamide,N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S...

CBNumber:: CB52455399

Molecular Formula:: C25H27F4N3O3S

Molecular Weight:: 525.56

MOL File:: 603139-19-1.mol

Modify Date:: 2024/3/27 16:59:26

Request For Quotation

MK-0822 Properties

Melting point	223-224 °C
Boiling point	681.6±55.0 °C(Predicted)
Density	1.35
storage temp.	Sealed in dry,Store in freezer, under -20°C
solubility	Chloroform (Slightly, Heated, Sonicated), Methanol (Slightly, Sonicated)
form	Solid
pka	12.06±0.20(Predicted)
color	White to Off-White
Stability	Hygroscopic

SAFETY

Risk and Safety Statements

Symbol(GHS)

GHS08

Signal word

Danger

Hazard statements

H373

Precautionary statements

P260-P314-P501

NFPA 704

	0
2		0

MK-0822 Chemical Properties,Uses,Production

Uses

MK-0822 is a newly developed bone-targeting dual action pro-drug for osteoporosis and bone metastasis. It is also an inhibitor of cathepsin K, an enzyme involved in bone resorption.

Enzyme inhibitor

This investigational osteoporosis/bone-metastasis drug (FW = 525.56 g/mol; CAS 603139-19-1), also known by the code name MK-0822 and its systematic name N-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro- 1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide, targets the cathepsin K, a unique collagenolytic lysosomal cysteine protease that is secreted, thereby facilitating bone resorption by cleaving type-1 collagen under acidic pH. Cathepsin K exhibits a unique cleavage pattern of type I collagen molecules that is fundamentally different from that of other endogenous collagenases. Women receiving ODN (10-50 mg) for 5 years had gains in spine and hip bone mineral density (BMD), showing larger reductions in bone resorption than bone formation markers. Significantly, discontinuation of ODN resulted in reversal of treatment effects. An odanacatib synthesis, which describes a novel stereospecific SN2 triflate displacement of a chiral a-trifluoromethylbenzyl triflate with (S)-g-fluoroleucine ethyl ester, achieves a 61% overall yield in 6 steps.

MK-0822 Preparation Products And Raw materials

Raw materials

Preparation Products

MK-0822 Suppliers

Global( 163)Suppliers

Supplier	Tel	Country	ProdList	Advantage	Inquiry
CLEARSYNTH LABS LTD.	+91-22-45045900	Hyderabad, India	6351	58	Inquiry
CHEMSWORTH	+91-261-2397244	New Delhi, India	6707	30	Inquiry
A.J Chemicals	91-9810153283	New Delhi, India	6124	58	Inquiry
Henan Fengda Chemical Co., Ltd	+86-371-86557731 +86-13613820652	China	20361	58	Inquiry
Alpha Biopharmaceuticals Co., Ltd	+86-15542445688	China	888	58	Inquiry
career henan chemical co	+86-0371-86658258 +8613203830695	China	29901	58	Inquiry
BOC Sciences	+1-631-485-4226	United States	19553	58	Inquiry
Chongqing Chemdad Co., Ltd	+86-023-6139-8061 +86-86-13650506873	China	39916	58	Inquiry
CONIER CHEM AND PHARMA LIMITED	+8618523575427	China	49391	58	Inquiry
Dorne Chemical Technology co. LTD	+86-86-13583358881 +8618560316533	China	3148	58	Inquiry

Supplier	Advantage
CLEARSYNTH LABS LTD.	58
CHEMSWORTH	30
A.J Chemicals	58
Henan Fengda Chemical Co., Ltd	58
Alpha Biopharmaceuticals Co., Ltd	58
career henan chemical co	58
BOC Sciences	58
Chongqing Chemdad Co., Ltd	58
CONIER CHEM AND PHARMA LIMITED	58
Dorne Chemical Technology co. LTD	58

MK-0822 Spectrum

MK-0822(603139-19-1)¹HNMR

603139-19-1(MK-0822)Related Search:

Cyanoacetic acid Benzonitrile 5'-D(ATGAAAATCAGGGTTAGG)-3', SODIUM SALT PD168393 MK-1775

Saracatinib Ibrutinib Olaparib Pentanamide N-(2-(BENZYLAMINO)ETHYL) CYCLOPROPANAMINE

Odanacatib (MK-0822)

chevron_left

1of3

chevron_right

Odanacatib,MK-0822,MK0822 Pentanamide, N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]-, (2S)- (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]pentanamide Odanacatib (MK-0822) Odanacatib (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]pentanamide (S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-((S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)biphenyl-4-yl)ethylamino)pentanamide Odanacatib, >=98% MK-0822 ODANACATIB (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]pentanamide Unii-N673F6W2vh N-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide Odanacatib(Mk0822) (S)-N-(1-cyanocyclopropyl)-4-fluoro-4-Methyl-2-(((S)-2,2,2-trifluoro-1-(4'-(Methylsulfonyl)-[1,1'-biphenyl]-4-yl)ethyl)aMino)pentanaMide (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-Methyl-2-{[(1S)-2,2,2-trifluoro-1-[4-(4-Methanesulfonylphenyl)phenyl]ethyl]aMino}pentanaMide CS-700 MK-0822;MK0822 (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide (MK0822,Odanacatib) Pentanamide,N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S... (S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-(((S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)ethyl)amino)pentanamide 603139-19-1 C25H27F4N3O3S API Inhibitors